title: Preliminary results of (125)I interstitial brachytherapy for locally recurrent parotid gland cancer in previously irradiated patients.
abstract: BACKGROUND
  The purpose of this study was to analyze the treatment of recurrent parotid gland cancers with radioactive iodine ((125)I) seed implantation.
  
  
  METHODS
  Fifteen patients with recurrent previously irradiated parotid gland cancers were treated with postoperative (125)I seed implantation between April 2004 and June 2009. Local control, survival rates, and side effects were retrospectively reviewed.
  
  
  RESULTS
  The 3-year and 5-year local control rates were 67% and 53.6%, and the overall survival rates were 76.2% and 66.7%, respectively. Four patients with House-Brackman (H-B) grade IV cancer recovered to grade II during follow-up. Four patients (26.7%) developed grade IV skin ulceration. Two patients (13.3%) developed moderate fibrosis of the subcutaneous tissues, and 2 patients (13.3%) had hearing loss for 1 year after brachytherapy.
  
  
  CONCLUSIONS
  This study showed excellent local control and a good survival rate in patients who received (125)I brachytherapy. These findings should be interpreted cautiously due to the small number of patients and the relatively short follow-up.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, People's Republic of China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zheng
authors.forename: Jianguo
authors.initials: J
authors.lastname: Zhang
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Tieli
authors.initials: T
authors.lastname: Song
authors.forename: Mingwei
authors.initials: M
authors.lastname: Huang
authors.forename: Guangyan
authors.initials: G
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D010307:Parotid Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D011855:Radiodermatitis / Q000175:diagnosis / Q000628:therapy; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007457:Iodine Radioisotopes